Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nexalin Technology (NXL) Common Equity (2021 - 2026)

Nexalin Technology has reported Common Equity over the past 5 years, most recently at $3.7 million for Q4 2025.

  • For Q4 2025, Common Equity rose 1.96% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, up 1.96%, while the annual FY2025 figure was $3.7 million, 1.96% up from the prior year.
  • Common Equity for Q4 2025 was $3.7 million at Nexalin Technology, down from $4.8 million in the prior quarter.
  • Over five years, Common Equity peaked at $6.4 million in Q3 2022 and troughed at -$2.2 million in Q2 2022.
  • A 5-year average of $2.7 million and a median of $3.5 million in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: surged 425.74% in 2022 and later plummeted 66.17% in 2024.
  • Year by year, Common Equity stood at -$1.7 million in 2021, then surged by 425.74% to $5.5 million in 2022, then plummeted by 41.47% to $3.2 million in 2023, then rose by 14.64% to $3.7 million in 2024, then grew by 1.96% to $3.7 million in 2025.
  • Business Quant data shows Common Equity for NXL at $3.7 million in Q4 2025, $4.8 million in Q3 2025, and $6.0 million in Q2 2025.